Novel Targeted Carriers for Brain Tumor Theranostics

Neurological diseases such as cancers,
neurodegenerative diseases, infections, pain, and
psychiatric disorders are a leading cause of disability,
morbidity, and mortality, affecting more than 1.5 billion
people worldwide, with the number rising if curative
treatments fail to emerge (Lalatsa & Barbu, 2016). Delivery
of therapeutics to the brain is difficult, as the vast majority
of therapeutic agents are excluded from the brain by the
blood brain barrier (BBB). Poor delivery to the brain
remains the bottleneck in the development of central nervous
system therapies (Pardridge, 2005) resulting in long
drug development times and a high failure rate in clinical.